+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Gabapentin Market by Product, Route of Administration, Medication, Application, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6016490
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Gabapentin Market grew from USD 2.22 billion in 2023 to USD 2.32 billion in 2024. It is expected to continue growing at a CAGR of 4.38%, reaching USD 3.00 billion by 2030.

Gabapentin is a medication primarily used to treat nerve-related pain and seizure disorders. Its market scope encompasses various applications, including the management of neuropathic pain, epilepsy, and migraine prevention. The necessity for Gabapentin arises from its effectiveness in treating these chronic conditions, providing an alternative for patients who may not respond to traditional painkillers or antiepileptics. The primary end-use sectors are healthcare providers, including hospitals and clinics, making Gabapentin a crucial pharmaceutical in neurology and pain management. Key growth factors influencing the Gabapentin market include an increasing prevalence of nerve-related disorders, rising awareness about mental health, and advancements in treatment methodologies. Additionally, the aging global population contributes to a higher demand for pain management solutions. Emerging markets, with their expanding healthcare infrastructures, present potential opportunities for market expansion. However, the challenge of patent expirations and the subsequent introduction of generic alternatives may hinder market growth, alongside potential side effects and the risk of misuse. Despite these challenges, innovation in formulation and delivery methods, such as extended-release versions and novel combination therapies, offer promising avenues for development. Regulatory pressures and increased scrutiny over prescription practices also shape the market dynamics, necessitating strategic approaches to compliance. Research and development focused on enhancing efficacy while minimizing side effects can lead to breakthroughs that set businesses apart. Enterprises can invest in technologies like artificial intelligence to optimize supply chain efficiencies and personalize treatment plans, ensuring a competitive edge. Overall, the Gabapentin market is evolving, driven by a blend of clinical needs and technological advancements, presenting substantial opportunities for growth, provided companies navigate the associated regulatory and competitive landscapes effectively.

Understanding Market Dynamics in the Gabapentin Market

The Gabapentin Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising incidences of chronic pain and related conditions increasing the need for effective treatment options
    • Integration of gabapentin in multimodal pain management regimens promoting its adoption in clinical practice
    • Government initiatives and healthcare policies favoring the availability and affordability of essential medications
  • Market Restraints
    • Competition from alternative therapies and counterfeit and cheap-quality drugs
  • Market Opportunities
    • Growing need for gabapentin in veterinary medicine for pain management in pets and livestock
    • Emergence of gabapentin as a key drug in the treatment of fibromyalgia and related chronic pain syndromes
    • Development of gabapentin-based combination therapies for enhanced treatment efficacy in neurological disorders
  • Market Challenges
    • Increasing concerns over potential side effects and misuse

Exploring Porter’s Five Forces for the Gabapentin Market

Porter’s Five Forces framework further strengthens the insights of the Gabapentin Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Gabapentin Market

External macro-environmental factors deeply influence the performance of the Gabapentin Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Gabapentin Market

The Gabapentin Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Gabapentin Market

The Gabapentin Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Gabapentin Market

The Gabapentin Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gabapentin Market, highlighting leading vendors and their innovative profiles. These include AVEFLOR, a. s., BD Custom Manufacturing, Capital Resin Corporation, Chemplast Sanmar Limited, Con-Tech International., Custom Manufacturing Corporation, Custom Manufacturing Solutions, Dassault Systèmes, Dassault Systèmes S.E., East West Manufacturing, LLC, Evonik Industries AG, Formlabs Inc., Ganesh Group of Industries, Grand Prix International PLC, Hexagon AB, Monroe Engineering, LLC, Promega Corporation., Protocase Incorporated, RAS Polska Sp. z o.o., Sartorius AG, SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD, Siemens AG, Thomas Swan & Co. Ltd., and VWR International, LLC..

Market Segmentation & Coverage

This research report categorizes the Gabapentin Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Capsule
    • Tablet
  • Route of Administration
    • Oral
    • Parenteral
  • Medication
    • Branded
    • Generic
  • Application
    • Anxiety
    • Epilepsy
    • Neuropathic Pain
    • Restless Legs Syndrome
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of chronic pain and related conditions increasing the need for effective treatment options
5.1.1.2. Integration of gabapentin in multimodal pain management regimens promoting its adoption in clinical practice
5.1.1.3. Government initiatives and healthcare policies favoring the availability and affordability of essential medications
5.1.2. Restraints
5.1.2.1. Competition from alternative therapies and counterfeit and cheap-quality drugs
5.1.3. Opportunities
5.1.3.1. Growing need for gabapentin in veterinary medicine for pain management in pets and livestock
5.1.3.2. Emergence of gabapentin as a key drug in the treatment of fibromyalgia and related chronic pain syndromes
5.1.3.3. Development of gabapentin-based combination therapies for enhanced treatment efficacy in neurological disorders
5.1.4. Challenges
5.1.4.1. Increasing concerns over potential side effects and misuse
5.2. Market Segmentation Analysis
5.2.1. Formulation: High preference for capsules due to convenient and straightforward option
5.2.2. Application : Widely utilized as an adjunct therapy for partial seizures to stabilize neuronal activity and reduce seizure frequency
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Gabapentin Market, by Product
6.1. Introduction
6.2. Capsule
6.3. Tablet
7. Gabapentin Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Parenteral
8. Gabapentin Market, by Medication
8.1. Introduction
8.2. Branded
8.3. Generic
9. Gabapentin Market, by Application
9.1. Introduction
9.2. Anxiety
9.3. Epilepsy
9.4. Neuropathic Pain
9.5. Restless Legs Syndrome
10. Gabapentin Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Americas Gabapentin Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Gabapentin Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Gabapentin Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Strides Pharma receives USFDA approval for neurology medication Gabapentin
14.3.2. Lotus and Adalvo launch Gabapentin ER in South Korea
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. GABAPENTIN MARKET RESEARCH PROCESS
FIGURE 2. GABAPENTIN MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 15. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. GABAPENTIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GABAPENTIN MARKET DYNAMICS
TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEGS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. CANADA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 42. CANADA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. CANADA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. MEXICO GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 47. MEXICO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 48. MEXICO GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 49. MEXICO GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES GABAPENTIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. CHINA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 69. CHINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. CHINA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 71. CHINA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. CHINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. INDIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. INDIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. INDIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 76. INDIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. INDIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. JAPAN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 84. JAPAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. JAPAN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 86. JAPAN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. JAPAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. THAILAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 114. THAILAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. THAILAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 116. THAILAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. THAILAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. DENMARK GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 130. DENMARK GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. DENMARK GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 132. DENMARK GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. DENMARK GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. EGYPT GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. EGYPT GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. EGYPT GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 137. EGYPT GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. EGYPT GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. FINLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. FINLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. FINLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 142. FINLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. FINLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. FRANCE GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 145. FRANCE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. FRANCE GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 147. FRANCE GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. GERMANY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 150. GERMANY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. GERMANY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 152. GERMANY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. ITALY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 160. ITALY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. ITALY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 162. ITALY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. NORWAY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 175. NORWAY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. NORWAY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 177. NORWAY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. NORWAY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. POLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 180. POLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. POLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 182. POLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. POLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. QATAR GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 185. QATAR GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. QATAR GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SPAIN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 205. SPAIN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 207. SPAIN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. TURKEY GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 220. TURKEY GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. TURKEY GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2023
TABLE 235. GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Gabapentin Market, which are profiled in this report, include:
  • AVEFLOR, a. s.
  • BD Custom Manufacturing
  • Capital Resin Corporation
  • Chemplast Sanmar Limited
  • Con-Tech International.
  • Custom Manufacturing Corporation
  • Custom Manufacturing Solutions
  • Dassault Systèmes
  • Dassault Systèmes S.E.
  • East West Manufacturing, LLC
  • Evonik Industries AG
  • Formlabs Inc.
  • Ganesh Group of Industries
  • Grand Prix International PLC
  • Hexagon AB
  • Monroe Engineering, LLC
  • Promega Corporation.
  • Protocase Incorporated
  • RAS Polska Sp. z o.o.
  • Sartorius AG
  • SHENZHEN WEIKE RAPID PROTOTYPING TECHNOLOGY CO. LTD
  • Siemens AG
  • Thomas Swan & Co. Ltd.
  • VWR International, LLC.

Methodology

Loading
LOADING...

Table Information